All In MedTech

Device Trial Radar · NCT06038695

Immediate Implant Placement Using Volume-Stable Collagen Matrix Combined With rhPDGF-BB

Ultrasound-based Imaging to Detect Early Changes of Hard and Soft Tissue Around Immediately Placed Implants With Volume-Stable Collagen Matrix Combined With rhPDGF-BB: Pilot Study

Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 2025

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
I-Ching WangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 15, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to test a volume-stable collagen matrix in combination with recombinant human platelet-derived growth factor-BB, specifically in patients who have an immediate implant placement for teeth #5-#12. The main question this study aims to answer is does the recombinant human platelet-derived growth factor-BB accelerate the formation of blood vessels and augment tissue volume around the immediate implant. Participants will be asked to undergo immediate implant placement using volume-stable collagen matrix in combination with recombinant human platelet-derived growth factor-BB, as well as attend 11 study visits over the course of 1.25 years.

Conditions

  • Tooth Extraction
  • Immediate Implant Placement

Interventions

  • Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BBDevice

    * Fibro-Gide is the Volume-Stable Collagen Matrix. * Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in from Baseline in Soft and Hard Tissue Thickness as assessed by ultrasound.Time frame: Multiple time points (i.e. 0, Immediately after implant placement, 1 week, 2 weeks, 4 weeks, 6 weeks, 12 weeks, 16 weeks, 24 weeks, and 48 weeks after immediate implant placement

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Iowa College of Dentistry and Dental Clinics

    Iowa City, Iowa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.